TokenPost·
Bernstein Downgrades Summit Therapeutics to Underperform on R&D Concerns

The FDA declined to approve ivonescimab, Summit’s lead asset developed with partner Akeso in China.
Every crypto headline. One feed. Updated every minute.

The FDA declined to approve ivonescimab, Summit’s lead asset developed with partner Akeso in China.